Literature DB >> 15048705

Alternative processing for MHC class I presentation by immature and CpG-activated dendritic cells.

Liying Chen1, Mikael Jondal.   

Abstract

Exogenous proteins can be processed by antigen-presenting cells for the generation of MHC class I-restricted T cell responses. Where this occurs is not clear, although both transfer of internalized antigen into the cytosol and alternative processing in endolysosomes and phagosomes have been reported. Here we have studied the capacity of bone marrow-derived mouse myeloid dendritic cells (DC) to process the OVA protein for peptide presentation by H2-K(b). We have found that immature DC (iDC), both wild-type and transporter associated with antigen processing (TAP)-deficient cells, can transiently process OVA in a pathway which is resistant to inhibitors of the classical MHC class I pathway including the Golgi inhibitor Brefeldin A (BFA) and the proteasome inhibitor lactacystin. This alternative pathway is not found in subcultured DC with an intermediate maturity (imDC) or in resting, IL-3 expanded macrophages but can be re-expressed in imDC if these are activated by an immunostimulatory CpG oligonucleotide. Both iDC and CpG-activated DC were found to process OVA by regurgitation. In addition, we found that iDC secrete proteolytic enzymes into the supernatant, which can process OVA in the extracellular phase. These results suggest that multiple pathways exist for the processing of exogenous protein antigens into MHC class I-binding peptides.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15048705     DOI: 10.1002/eji.200324359

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.

Authors:  Mitsuhiro Iyori; Tong Zhang; Haddon Pantel; Bethany A Gagne; Charles L Sentman
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

2.  Lactation-Based Maternal Educational Immunity Crosses MHC Class I Barriers and Can Impart Th1 Immunity to Th2-Biased Recipients.

Authors:  Mrinal K Ghosh; H Konrad Muller; Ameae M Walker
Journal:  J Immunol       Date:  2017-07-26       Impact factor: 5.422

3.  The same well-characterized T cell epitope SIINFEKL expressed in the context of a cytoplasmic or secreted protein in BCG induces different CD8+ T cell responses.

Authors:  Paul D Hulseberg; Alla Zozulya; Hamlet H Chu; James A Triccas; Zsuzsanna Fabry; Matyas Sandor
Journal:  Immunol Lett       Date:  2009-12-11       Impact factor: 3.685

4.  Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity.

Authors:  Olivier Renaudet; Gargi Dasgupta; Ilham Bettahi; Alda Shi; Anthony B Nesburn; Pascal Dumy; Lbachir BenMohamed
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

5.  Using the TAP component of the antigen-processing machinery as a molecular adjuvant.

Authors:  Timothy Z Vitalis; Qian-Jin Zhang; Judie Alimonti; Susan S Chen; Genc Basha; Alex Moise; Jacqueline Tiong; Mei Mei Tian; Kyung Bok Choi; Douglas Waterfield; Andy Jeffries; Wilfred A Jefferies
Journal:  PLoS Pathog       Date:  2005-12-30       Impact factor: 6.823

6.  Cryptococcus neoformans Escape From Dictyostelium Amoeba by Both WASH-Mediated Constitutive Exocytosis and Vomocytosis.

Authors:  Rhys A Watkins; Alexandre Andrews; Charlotte Wynn; Caroline Barisch; Jason S King; Simon A Johnston
Journal:  Front Cell Infect Microbiol       Date:  2018-04-09       Impact factor: 5.293

Review 7.  Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation.

Authors:  Fabian Junker; John Gordon; Omar Qureshi
Journal:  Front Immunol       Date:  2020-07-03       Impact factor: 7.561

8.  MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy.

Authors:  David Possamaï; Laïla-Aïcha Hanafi; Angélique Bellemare-Pelletier; Katia Hamelin; Paméla Thébault; Marie-Josée Hébert; Étienne Gagnon; Denis Leclerc; Réjean Lapointe
Journal:  PLoS One       Date:  2021-12-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.